Optimizing immunotherapy for neuroblastoma
Neuroblastoma is a pediatric tumor of the sympathic nervous system. The immunontherapy Dinutuximab against GD2 has led to a small increase in the survival of patients with high-risk neuroblastoma. Therefore, immunotherapies are promising treatment strategies for neuroblastoma.
In this project we will investigate immunosuppressive factors in the tumor microenvironment and tumor specific targets in order to improve immunotherapies for neuroblastoma, including B7H3 CAR-T cells and anti-GD2 immunotherapy.
Contact
Anne Borst